Tu1549: IMPLEMENTATION AND SHORT-TERM ADVERSE EVENTS OF ANTI-SARSCOV-2 VACCINES IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTERNATIONAL WEB-BASED SURVEY

reviewers.Relevant conference abstracts were manually reviewed to identify additional studies.Studies that reported the willingness or rate of COVID vaccination, the adverse events, and/or efficacy of the COVID vaccine among IBD patients were included.Efficacy was defined as the ability of a vaccine to produce detectable antibodies.Meta-analysis was performed using a bivariate random-effects model.RESULTS 2049 studies were identified through database search and additional 10 conference abstracts were extracted.24 studies, with the majority (79%) from North America or Europe were included.Four studies reported the rate of adverse events of vaccines ranging from 39% to 74% after the first and second doses of vaccine, respectively.Pooled estimates of nine studies showed that only 59% of IBD patients (95% confidence interval (CI):39%-79%) were willing or had already received a vaccine.Pooled estimates of six studies showed the vaccine was 96% (95% CI: 92%-99%) effective in creating seroconversion in IBD patients.Three studies reported the incidence of break-through infection following COVID vaccination; The pooled estimates showed no statistically significant difference between the risk ratio of IBD patients versus healthy control (Risk difference:0.02(95%CI: -0.02, 0.06), P-value:0.3).Mean values of antibody level were statistically significantly lower in IBD patients receiving immunosuppression compared with those who were not on immunosuppression (Standardized mean difference: -0.38 (95% CI: -0.58, -0.18), P-value:0.002).CONCLUSION COVID vaccines are protective against preventing COVID-19 infection in IBD patients.However, patients on immunosuppression may have reduced response and could benefit from a booster dose.More importantly, there should be more efforts in encouraging IBD patients towards vaccination.Additionally, is scarce data and further studies are required to assess the global effect of the COVID vaccine in IBD patients, particularly in underdeveloped countries. Tu1548